Safety data in hand, Oncbiomune plies prostate cancer immunotherapy
Oncbiomune Pharmaceuticals Inc. is pressing ahead with a phase II trial of Proscavax, its therapeutic vaccine to treat prostate cancer, after preliminary data from a small phase I trial showed the treatment was safe and suggested initial indications of efficacy.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST